Featured Question

For which patient populations are the newer cholesterol-modifying drugs targeted/indicated and why—ie, are high–cardiovascular-risk patients with severe hypercholesterolemia and patients with familial hypercholesterolemia (FH) most likely to derive benefit from them, or are they also applicable to patients who are resistant or intolerant to statin therapy?

See The Answer

Get the latest
science delivered
to your inbox

Answers in CME updates are
available in YOUR specialty.

Sign-up Now!

Featured Activities


Challenging Cases in Multiple Sclerosis

Course Director
Aaron E. Miller, MD
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, New York